The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (Q37784691)

23 August 2017

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (English)

1 reference

23 August 2017

1 reference

R Garcia-Sanz

8

0 references

Athanasios Dimopoulos

2

object named as

M A Dimopoulos

1 reference

International Myeloma Working Group

23 August 2017

17

object named as

International Myeloma Working Group

1 reference

23 August 2017

16

B G M Durie

1 reference

23 August 2017

E Terpos

1

1 reference

23 August 2017

O Sezer

3

1 reference

23 August 2017

D Roodman

4

1 reference

23 August 2017

N Abildgaard

5

1 reference

23 August 2017

R Vescio

6

1 reference

23 August 2017

P Tosi

7

1 reference

23 August 2017

F Davies

9

1 reference

23 August 2017

A Chanan-Khan

10

1 reference

23 August 2017

A Palumbo

11

1 reference

23 August 2017

P Sonneveld

12

1 reference

23 August 2017

M T Drake

13

1 reference

23 August 2017

J-L Harousseau

14

1 reference

23 August 2017

K C Anderson

15

1 reference

23 August 2017

2 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

24

1 reference

23 August 2017

10

1 reference

23 August 2017

1700-1712

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.173

23 August 2017

0 references

cites work

Bisphosphonates: clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Myeloma bone disease: pathophysiology and management.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Pathogenesis of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Myeloma bone disease: recent advances in biology, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Bone marker nomenclature.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Gastrointestinal absorption and renal excretion of hydroxyproline peptides

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Development of an immunoassay for urinary galactosylhydroxylysine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Cross-linking in collagen and elastin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Carboxylated calcium-binding proteins and vitamin K.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Vitamin K-dependent proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Biochemical markers of bone metabolism: an overview

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Clinical review 165: Markers of bone remodeling in metastatic bone disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Biochemical bone markers in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Biochemical markers of bone turnover in diagnosis of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Content and distribution of noncollagenous matrix proteins in bone and cementum: relationship to speed of formation and collagen packing density

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Response to bortezomib and activation of osteoblasts in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.173

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.173

1 reference

Dimensions Publication ID

23 August 2017

1048496341

0 references

Fatcat ID

release_gcd4kkk57ngvld3oxsx4lm3mna

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gcd4kkk57ngvld3oxsx4lm3mna

24 November 2022

mapped directly with Wikidata item

1 reference